Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erfukang is a Traditional Chinese Medicine (TCM) topical formulation, primarily available as a lotion (Erfukang Chaji), specifically developed for pediatric dermatological care. It is indicated for the treatment of pediatric eczema, subacute eczema, dermatitis, and prickly heat. The formulation is a combination of several herbal extracts, including *Cnidium monnieri* (Shechuangzi), *Sophora flavescens* (Kushen), *Phellodendron amurense* (Huangbai), *Atractylodes lancea* (Cangzhu), and *Mentha haplocalyx* (Bohe). These ingredients contain active compounds such as osthole, matrine, and berberine, which collectively exert anti-inflammatory, antipruritic, and antimicrobial effects. Erfukang works by inhibiting pro-inflammatory cytokines and modulating histamine responses, providing a non-steroidal therapeutic option for managing skin irritation and itching in infants and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Erfukang.